CD8A and melanoma: Vaccination of melanoma patients in recent clinical trials using either synthetic long peptide or RNA-based vectoral approaches filtered for predicted MHC I binding revealed that anti-tumoral CD8+ T cell reactivity was accompanied by a significant CD4+ T cell MHC II-restricted component or sometimes contained single epitopes dually recognized by both CD4+ and CD8+ T cells (72, 73).